§ Federal grant opportunity · PA-25-163
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
National Institutes of Health is accepting applications for Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required). The deadline is September 7, 2026 and the published award range is $500K.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- September 7, 2026
- Award range
- $500K
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- PA-25-163
Program overview
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 7, 2026, allowing time for registration and validation.
Related grant opportunities
- Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
- Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
- Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
- Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
- Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.